SCHEMBL23924237

SCHEMBL23924237

Brc1nc(-c2cccnc2)cs1

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 12/20 0.69
AXL P30530 1/20 0.69
PBRM1 Q86U86 1/20 0.69
MKNK1 Q9BUB5 1/20 0.69
MKNK2 Q9HBH9 1/20 0.69
RAB9A P51151 2/20 0.65
NPC1 O15118 2/20 0.65
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
LMNA P02545 1/20 0.60
MAPT P10636 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
KDM4E B2RXH2 1/20 0.60
ALDH1A1 P00352 1/20 0.60
MAPK1 P28482 1/20 0.58
PKM P14618 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL128811 0.81 CYP19A1 (0.69) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL30098510 0.81 CYP19A1 (0.69) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL6196239 0.81 CYP19A1 (1.00) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL3613262 0.81 RAB9A (0.56) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL4656471 0.80 CYP19A1 (0.67) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL1807468 0.80 CYP19A1 (0.67) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL9571662 0.80 CYP19A1 (0.67) CYP19A1AXLPBRM1MKNK1MKNK2
Bromide SCHEMBL15689048 0.80 CYP19A1 (0.67) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL17014786 0.79 CYP19A1 (1.00) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL30128572 0.79 CYP19A1 (1.00) CYP19A1AXLPBRM1MKNK1MKNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118878514-A Heterocyclic compounds for modulating NR2F6 TES制药有限责任公司 2024-11-01 CN disclosed
CN-115427394-A Heterocyclic compounds for modulating NR2F6 TES制药有限责任公司 2022-12-02 CN disclosed
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S.R.L. (IT) 2022-07-07 US disclosed
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S R L (IT) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 CYP19A1 1508/4885AXL 3751/4885PBRM1 2301/4885
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 CYP19A1 1508/4885AXL 3751/4885PBRM1 2301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.